EASD 2026 28 September - 2 October 2026

3-Month Real-World Weight Outcomes Among Patients With Overweight or Obesity After Switching From Injectable Semaglutide or Tirzepatide to Oral Semaglutide for Weight Management: The OCTANE Study

Authors :

B.J. Smith¹;V. Divino²; C.S. Morgen³; L. Broffman¹; L. Wilson²; J. Bhavsar²; R. Manalac¹; R. Patel²; S. Chai¹; L.J. Aronne⁴; B.G. Tchang⁴

Affiliations

View Details Hide Details

Download poster (.pdf)

Keywords

Obesity

Congress short oral presentation

GLP-1 RA

Semaglutide (oral)

RWE

Are you a healthcare professional?